Advertisement

Topics

Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Company Profile

09:05 EST 12th December 2018 | BioPortfolio


News Articles [2095 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb Awards “Golden Tickets” to ReviveMed and Strand Therapeutics

Bristol-Myers Squibb and LabCentral, a Cambridge, Mass.-based shared laboratory space, announced the two winners of the Bristol-Myers Squibb’s 2018 Golden Tickets for LabCentral. Due to being a plat...

Bristol-Myers Squibb and Gritstone to start Phase l trial for tumours

Bristol-Myers Squibb Company has entered a clinical trial collaboration with Gritstone Oncology to examine the safety and tolerability of GRANITE-001...Read More... The post Bristol-Myers Squibb and G...

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combi...

Bristol-Myers Squibb and Infinity Pharmaceuticals Collaborate to Evaluate Opdivo in Combination with IPI-549 in Urothelial Cancer

NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration t...

Bristol-Myers Squibb to Take Part in Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York. Tom Lynch, chief scientific ...

Bristol-Myers Squibb Announces Departure of Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3...

Bristol-Myers Squibb and Infinity Pharmaceuticals to Evaluate Opdivo in Combination with IPI-549 in Urothelial Cancer

NewsIPI-549 is designed to selectively inhibit phosphoinositide-3-kinase PI3K-gamma and is the only investigational PI3K-gamma inhibitor in clinical development.Contrib

Bristol-Myers Squibb unveils data from Phase I/II mUC trial

Bristol-Myers Squibb has revealed follow-up data from the Phase I/II CheckMate -032 trial evaluating the safety and efficacy of Opdivo...Read More... The post Bristol-Myers Squibb unveils data from Ph...

PubMed Articles [2755 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid...

A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC).

Janssen Research & Development, LLC, part of the Janssen pharmaceutical companies of Johnson & Johnson, and NYU School of Medicine partnered to establish the Compassionate Use Advisory Committee (Comp...

What research is needed to validate new urodynamic methods? ICI-RS2017.

In recent years urodynamic innovations, although well researched, have failed to follow a standardized development pathway specifically in terms of clinical trials undertaken to demonstrate efficacy. ...

Personality Assessment for Employee Development: Ivory Tower or Real World?

The acceptance and popularity of personality assessments in organizational contexts has grown enormously over the last 40 years. Although these are used across many applications, such as executive co...

Clinical Trials [3748 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

This study compared the relative bioavailability (rate and extent of absorption) of Pravastatin Sodium Tablets 80 mg by Teva Pharmaceutical Industries, Ltd. with that of Pravachol® Tablet...

Companies [5771 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

More Information about "Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC news stories on BioPortfolio along with dozens of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Clinical Trials and PubMed Articles about Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Companies in our database. You can also find out about relevant Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record